Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/v13030436 http://scihub22266oqcxt.onion/10.3390/v13030436 33800528!8001057!33800528     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Viruses 2021 ; 13 (3): ä Nephropedia Template TP {{tp|p=33800528|t=2021. Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19 |pdf=|usr=}}{{33800528}} gab.com Text Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19 JO: Viruses http://www.kidney.de/pget.php?&tw=1&pmid=33800528 #FOAvip The use of convalescent plasma in the treatment of COVID-19 may lead to a milder course of infection and has been associated with improved outcomes. Determining optimal treatments in high risk populations is crucial, as is the case in those with hematological malignancies. We analyzed a cohort of 23 patients with hematological malignancies and COVID-19 who had received plasma 48-72 h after the diagnosis of infection and compared it with a historical group of 22 patients who received other therapy. Overall survival in those who received convalescent plasma was significantly higher than in the historical group (p = 0.03460). The plasma-treated group also showed a significantly milder course of infection (p = 0.03807), characterized by less severe symptoms and faster recovery (p = 0.00001). In conclusion, we have demonstrated that convalescent plasma is an effective treatment and its early administration leads to clinical improvement, increased viral clearance and longer overall survival in patients with hematological malignancies and COVID-19. To our knowledge, this is the first report to analyze the efficacy of convalescent plasma in a cohort of patients with hematological malignancies. Twit Text FOAVip Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19 ????Viruses http://www.kidney.de/pget.php?&tw=1&pmid=33800528 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33800528 #FOAvip English Wikipedia <ref>{{Cite pmid|33800528}}</ref> Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19 #MMPMID33800528 Biernat MM; Kolasinska A; Kwiatkowski J; Urbaniak-Kujda D; Biernat P; Janocha-Litwin J; Szymczyk-Nuzka M; Bursy D; Kalicinska E; Simon K; Mazur G; Wrobel T Viruses 2021[Mar]; 13 (3): ä PMID33800528show ga The use of convalescent plasma in the treatment of COVID-19 may lead to a milder course of infection and has been associated with improved outcomes. Determining optimal treatments in high risk populations is crucial, as is the case in those with hematological malignancies. We analyzed a cohort of 23 patients with hematological malignancies and COVID-19 who had received plasma 48-72 h after the diagnosis of infection and compared it with a historical group of 22 patients who received other therapy. Overall survival in those who received convalescent plasma was significantly higher than in the historical group (p = 0.03460). The plasma-treated group also showed a significantly milder course of infection (p = 0.03807), characterized by less severe symptoms and faster recovery (p = 0.00001). In conclusion, we have demonstrated that convalescent plasma is an effective treatment and its early administration leads to clinical improvement, increased viral clearance and longer overall survival in patients with hematological malignancies and COVID-19. To our knowledge, this is the first report to analyze the efficacy of convalescent plasma in a cohort of patients with hematological malignancies. |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |COVID-19 Serotherapy[MESH] |COVID-19/mortality/*therapy[MESH] |Cohort Studies[MESH] |Female[MESH] |Hematologic Neoplasms/*mortality/therapy[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Male[MESH] |Middle Aged[MESH] |Plasma/immunology[MESH] |Survival[MESH] |Treatment Outcome[MESH]Early Administration of Convalescent Plasma Improves Survival in Patie(epmc).pdf DeepDyve Pubget Overpricing